A Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer

NCT07652073 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic Ovarian Cancer

Interventions

DRUG: DAT-2645 tablet

Sponsor

Danatlas Pharmaceuticals Co., Ltd